PURA - Puration Expects Rapid EVERx CBD Infused Nutritional Supplement Product Expansion With 10 New Products
May 08 2017 - 10:41AM
InvestorsHub NewsWire
DALLAS, TX -- May 8, 2017
-- InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today released a letter to shareholders form CEO Brian
Shibley to highlight the anticipated benefits to PURA shareholders
expected in conjunction with the pending acquisition of a
controlling interest in PURA by American Cannabis Innovations
Conglomerated (“ACI”) announced last week. Highlights
addressed in his letter include the rapid expansion of the
Company’s EVERx CBD Infused Sports and Fitness Nutritional
Supplement product line and an overall share price enhancement of
PURA common shares.
Dear Shareholders –
Last week American Cannabis Conglomerated (“ACI”) announced the
pending acquisition of a controlling interest in PURA and PURA’s
sister company, North American Cannabis Holdings (USOTC:
USMJ). Steven Rash, the CEO of USMJ released a letter to
USMJ shareholders earlier today that covered some of the same
highlights I will cover here. However, even if you have
already read the Mr. Rash’s letter, read on here. I will
cover some shareholder benefits expected from the ACI transaction
that are unique to PURA shareholders.
ACI is a private equity backed rollup founded to combine a variety
of leading young cannabis companies with complimentary offerings
and synergistic operations. As the first two companies to be
acquired into the rollup, both PURA and USMJ management will play a
key rolls in ACI.
PURA Share Price Enhancement Potential
The goal of the ACI is to improve the market capitalization value
of otherwise undervalued cannabis sector companies by 1) improving
operating efficiencies made possible through the combination of
multiple operations under one roof and 2) improving the terms on
growth capital resources with investment that does not come with
excessive downward pressure on share prices.
No Reverse Split and No New Common Shares To Be
Issued
Since the announcement last week, both USMJ and PURA have received
some calls and emails from shareholders concerned about various
possible impacts to their current share positions. Let me clarify a
few concerns mentioned by shareholders. Both PURA and USMJ
common shares will remain publicly traded on the OTC Markets.
A reverse split of the common stock is NOT a required term of the
ACI transaction for either PURA or USMJ. ACI is acquiring a
control block of preferred shares in PURA and USMJ that do not
trade publicly. No new common shares of PURA or USMJ are
being issued as part of the ACI transaction. We sincerely
anticipate the ACI acquisition of PURA and USMJ control to enhance
the value of the common stock of both Companies.
Rapid Product Line Expansion of EVERx CBD Infused
Nutritional Supplements
The feature I am most excited about is the planned expansion of the
EVERx CBD Infused Sports and Fitness Nutritional Supplement product
line. In conjunction with the development of the of the ACI
transaction, ACI traveled with me to visit the production
facilities of Alkame Holdings, Inc. (USOTC:
ALKM). ALKM is PURA’s co-packing and formulation partner
in the production of EVERx products. PURA and ALKM have
developed plans to introduce another 10 EVERx CBD Infused Sports
and Fitness Nutritional Supplement products. ACI has endorsed
the plan and we expect to start introducing new products as early
as next month.
Check back frequently and look for the first new EVERx product
announcement coming soon.
Brian Shibley
CEO
Puration
Learn More About PURA:
purationinc.com
Disclaimer/Safe Harbor: This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies’ contracts, the companies’ liquidity position, the
companies’ ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure or prevent any disease.
Puration Contact:
Brian Shibley, CEO
info@purationinc.com
+1-214-937-9097
Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Alkame (CE) (USOTC:ALKM)
Historical Stock Chart
From Mar 2023 to Mar 2024